PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom.\', \'The Edmond J Safra Program in Parkinson\'s Disease, Toronto Western Hospital, University of Toronto, Toronto, Canada.\', \'Department of Neurology, Weill Institute for the Neurosciences, University of California San Francisco, and San Francisco Veterans Affairs Health Care System, San Francisco, California, USA.\', \'Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany.\', \'Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom.\', \'Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, London, United Kingdom.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/mds.28293
?:hasPublicationType
?:journal
  • Movement disorders : official journal of the Movement Disorder Society
is ?:pmid of
?:pmid
?:pmid
  • 32860226
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • The Impact of COVID-19 on Access to Parkinson\'s Disease Medication.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all